No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CVAC240719C2500
- 0.70
- -0.21-23.08%
15min DelayClose Jul 12 15:59 ET
0.70High0.70Low
0.70Open0.91Pre Close6 Volume113 Open Interest2.50Strike Price420.00Turnover189.03%IV-1.84%PremiumJul 19, 2024Expiry Date0.76Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8720Delta0.2417Gamma3.95Leverage Ratio-0.0128Theta0.0004Rho3.45Eff Leverage0.0010Vega
Intraday
- 5D
- Daily
News
Express News | CureVac NV: UK Trial on Validity of Intellectual Property Rights Ep 3 708 668 B1 and Ep 4 023 755 B1 Began July 10; Judgement Expected Later in 2024
Express News | CureVac NV - New Trial Date for U.S. Patent Litigation Set for March 3, 2025, Following Settlement With Acuitas Therapeutics
CureVac: A Buy Rating Amidst Intellectual Property Litigation and Strong Valuation Metrics
CureVac Announced The Latest Trial Dates For Its Ongoing Patent Litigation Against Pfizer/BioNTech In Multiple Geographies, Including The U.S., UK, And Germany
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology)
Express News | CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
Agomab Bolsters Executive Team With Appointment of Pierre Kemula as Chief Financial Officer
Comments
$CureVac(CVAC.US$ CureVac Announced The Latest Trial Dates For Its Ongoing Patent Litigation Against Pfizer/BioNTech In Multiple Geographies, Including The U.S., UK, And Germany
Benzinga· 1 min ago
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics.
First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent liti...
Benzinga· 1 min ago
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics.
First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent liti...
1
$CureVac(CVAC.US$ Good news and people still sell wtf lol
1
$CureVac(CVAC.US$ It's going up up up today the volume already almost as much as it was pre-market yesterday.After Novavax deal they rocketed!
$CureVac(CVAC.US$ GSK to Buy CureVac's Covid-19, Flu Vaccine Rights for Up to $1.56 Bln
4
10
Read more